Fischesser Ryan 4

4 · Caribou Biosciences, Inc. · Filed Jan 12, 2022

Form 4

Period: 2022-01-11

VP of Finance and Controller

Transactions

Exercise of In-Money
Option to purchase Common Stock
2022-01-11−569→ 6,815 total
Exercise: $2.69Exp: 2029-03-18→ Common Stock (569 underlying)
Purchase
Common Stock
2022-01-11$2.69/sh+569$1,531→ 102,264 total
Purchase
Common Stock
2022-01-11$4.11/sh+6,818$28,022→ 109,082 total
Exercise of In-Money
Option to purchase Common Stock
2022-01-11−6,818→ 20,452 total
Exercise: $4.11Exp: 2031-03-29→ Common Stock (6,818 underlying)

Footnotes (4)

[F1]These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below.
[F2]The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 23, 2021.
[F3]The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on January 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
[F4]1/4th of the shares subject to this option vested on January 1, 2022 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter, subject to the reporting person's continued services to the Issuer through the applicable vesting dates.

Documents

1 file